About Iverheal
Iverheal is a Healthcare company. Manufacturing and distributing antiparasitic medications and related pharmaceutical products. The company has 634 employees. Its Indian entity Healing Pharma India Private Limited reported revenue of ₹163 Cr. Iverheal offers products and services including Iverheal 12mg and Ivermectin 3mg. Its focus areas include Pharmaceuticals, Drug Manufacturing, Antiparasitic Medications and Healthcare Services.
Company details
Healing Pharma India , Established In 2018, Is Recognized For Producing Iverheal 12mg, Which Contains Ivermectin And Is Used To Address Parasitic Infections Such As Strongyloidiasis, River Blindness, And Scabies. The Company Focuses On Generic Medicines, Cosmetics, Herbal, Hormonal, And Nutraceutical Preparations, Providing Comprehensive Services In Drug Discovery And Medication Production. Ivermectins Antiviral And Anti-inflammatory Properties Are Also Noted, Though Its Primary Role Lies In Treating Intestinal And Tissue Parasites Effectively. Safety Precautions, Including Avoidance During Pregnancy, Are Emphasized In Its Usage Guidelines.
- Employees 634
- SectorsHealthcare
- Legal Name Healing Pharma India Pvt Ltd
- Date of Incorporation 25 Apr, 2018
- Jurisdiction Mumbai, Maharashtra, India
- Indian entity revenue₹163 Cr
FY 2025 · +34% YoY
- Indian entity net profit₹14.65 Cr
FY 2025 · 9% margin
- Indian entity EBITDA₹20.75 Cr
FY 2025 · 13% margin
- Employee Count634
Associated legal entities of Iverheal
Iverheal operates through Healing Pharma India Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Healing Pharma India Private Limited CIN U24100MH2018PTC308533 | Active | 25 Apr 2018 | Mumbai, Maharashtra | ₹163 Cr | 634 | 2 | View details |
Products & Services of Iverheal
Iverheal offers a comprehensive portfolio of products and services, including Iverheal 12mg and Ivermectin 3mg.
Iverheal 12mg is utilized for treating parasitic infections of the skin, eyes, and gastrointestinal tract by targeting and eliminating parasites
Ivermectin 3mg is employed for managing various parasitic conditions, including strongyloidiasis and other infections, as part of the product range
Board of directors of Healing Pharma India Private Limited (Iverheal)
Healing Pharma India Private Limited is the primary company behind Iverheal. The board of Healing Pharma India Private Limited currently have 2 directors; the longest-serving is Hitesh Madanlal Jain, appointed in 2018. 4 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Hitesh Madanlal Jain DIN 05203102 | Managing Director | 25 Apr 2018 | 8 yrs 5 mo | Healing Pharma India Private Limited |
| Sanjay Sampatraj Parekh DIN 05300125 | Managing Director | 25 Apr 2018 | 8 yrs 5 mo | Healing Pharma India Private Limited |
Financials of Iverheal
Figures of Healing Pharma India Private Limited, the primary company behind Iverheal, for FY 2025. Revenue was ₹163 Cr (+34% year on year). Net profit was ₹14.65 Cr (9% margin). EBITDA was ₹20.75 Cr (13% margin). Revenue has grown at a compounded annual rate of +27% over three years and +37% over five years.
- ₹163 CrRevenue · FY 2025 · +34% YoY
- ₹14.65 CrNet profit · 9% margin
- ₹20.75 CrEBITDA · 13% margin
- ₹4 LakhPaid-up capital
- 634Employees (provident fund records)
- +27%Revenue CAGR, 3 years
- +37%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Healing Pharma India Private Limited are on its company page.
Detailed financial statements for Iverheal
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Iverheal
Complete news archive for Iverheal
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Iverheal
Iverheal has 634 employees.
The primary company behind Iverheal, Healing Pharma India Private Limited, reported revenue of ₹163 Cr for FY 2025, up 34% year on year.
Healing Pharma India , Established In 2018, Is Recognized For Producing Iverheal 12mg, Which Contains Ivermectin And Is Used To Address Parasitic Infections Such As Strongyloidiasis, River Blindness, And Scabies. The Company Focuses On Generic Medicines, Cosmetics, Herbal, Hormonal, And Nutraceutical Preparations, Providing Comprehensive Services In Drug Discovery And Medication Production. Ivermectins Antiviral And Anti-inflammatory Properties Are Also Noted, Though Its Primary Role Lies In Treating Intestinal And Tissue Parasites Effectively. Safety Precautions, Including Avoidance During Pregnancy, Are Emphasized In Its Usage Guidelines.
Iverheal offers Iverheal 12mg and Ivermectin 3mg.
Iverheal operates through Healing Pharma India Private Limited.
The legal entities of Iverheal currently have 2 directors, including Hitesh Madanlal Jain, Sanjay Sampatraj Parekh.